Immune cells take on tough tumors in early trial
NCT ID NCT06088472
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study will also see if tumors shrink. About 12 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart RAS-Mutant cancers?
- Could a personal coach at home boost energy for cancer patients?
- Personalized maintenance therapy: a smarter way to treat advanced cancer?
- Can a radioactive antibody light up hidden cancers on PET scans?
- Can a smart drug deliver a toxic payload directly to cancer cells?
- Fighting cancer wasting: can diet and exercise make olanzapine work better?